Medicover saw the highest growth of 0.99% in patent filings in June and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Medicover’s patent filings and grants. Buy the databook here.
Medicover has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 100% of filings. The United States(US) patent Office are among the top ten patent offices where Medicover is filings its patents..
Regeneron Pharmaceuticals and Roche could be the strongest competitors for Medicover
Patents related to rare diseases lead Medicover's portfolio
Medicover has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Cerebral infarction (brain infarction) related patents lead Medicover portfolio followed by multiple sclerosis, and amyotrophic lateral sclerosis
Medicover has highest number of patents in cerebral infarction (brain infarction) followed by multiple sclerosis, amyotrophic lateral sclerosis, parkinson's disease, and alzheimer's disease.
For comprehensive analysis of Medicover's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.